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Abstract Preimplantation aneuploidy screening of cleav-
age stage embryos using fluorescence in situ hybridization
(FISH) may no longer be considered the standard of care in
reproductive medicine. Over the last few years, there has
been considerable development of novel technologies for
comprehensive chromosome screening (CCS) of the human
genome. Among the notable methodologies that have been
incorporated are whole genome amplification, metaphase
and array based comparative genomic hybridization, single
nucleotide polymorphism microarrays, and quantitative
real-time PCR. As these methods become more integral
to treating patients with infertility, it is critical that
clinicians and scientists obtain a better understanding
of their capabilities and limitations. This article will
focus on reviewing these technologies and the evidence
of their validity.
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The concept of preimplantation genetic screening (PGS) for
chromosomal abnormalities to improve clinical outcomes in
patients undergoing in vitro fertilization (IVF) is based on the
observation that aneuploidy represents the leading genetic
cause of miscarriage [1] and is likely the most prevalent
genetic abnormality in human embryos [2]. In addition, con-
ventional embryo selection methodologies, namely using
morphological and developmental criteria, are not sufficient
to identify which embryos are chromosomally normal [3].
DespitesoundprinciplesfortheuseofPGS,clinicaloutcomes
from FISH based PGS, the most commonly used technology,
have been disappointing [4].
One of the key limitations of FISH based preimplantation
aneuploidy screening is the inability to simultaneously evalu-
ate all 24 chromosomes found in human cells (chromosome 1–
22, X and Y). The development of technologies for single cell
whole genome amplification [5–9] has now led to a number of
methodologies for comprehensive screening of all 24 chromo-
somes in preimplantation embryos and polar bodies. These
CCS technologies include metaphase comparative genomic
hybridization (mCGH) [10–12], array (a)CGH [5, 6, 13, 14],
and single nucleotide polymorphism (SNP) arrays [15–19].
More recently, a quantitative real time (q)PCR approach was
developed that does not require whole genome amplification
[20]. Despite similar applications (i.e. 24 chromosome aneu-
ploidy screening) these various methods of CCS possess
unique capabilities and limitations (Table 1).
Capsule With renewed interest in embryo selection through
comprehensive aneuploidy screening, a review of the capabilities,
limitations, and evidence of validity of new methodologies including
array CGH, SNP microarrays, and real-time PCR is provided.
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quired to complete the analysis. While rapid conventional
mCGH methods have been developed [21–23], the most
widely used methods aren’t suitable for cleavage stage bi-
opsy and fresh embryo transfer. However, mCGH results are
typically available in time for a fresh embryo transfer when
applied to polar body biopsy [12, 24]. Currently, most
groups utilize aCGH instead of mCGH in clinical trials
and commercial activities as aCGH allows for greater
throughput, higher resolution and more rapid analyses.
SNP arrays can also be used on blastomeres in time for
fresh embryo transfer [16, 25] and additional time savings
are possible through the use of qPCR methods from which
results are available within 4 h of the biopsy allowing fresh
blastocyst transfer after trophectoderm biopsy [20, 26].
Although aCGH and SNP array technology both involve
an array of DNA based probes, these methods are not
equivalent. For example, among the commonly used arrays
for PGS, the BlueGnome (Cambridge, UK) bacterial artifi-
cial chromosome (BAC) arrays possess approximately
2,000 to 5,000 DNA probes across 24 chromosomes [27],
the Affymetirx (Santa Clara, CA) NspI SNP array possesses
approximately 262,000 probes [15, 28], and Illumina (San
Diego, CA) arrays used typically possess approximately
300,000 to 370,000 probes [16–18]. Although the number
of probes included on each of these arrays does not neces-
sarily correlate with the level of accuracy, it does influence
the level of genomic resolution provided by each method.
Furthermore, BAC array and SNP array probe numbers may
not be directly compared since relative performance of
probes on each array type can impact resolution. While it
is clear that whole chromosome aneuploidy represents the
most common and clinically relevant genetic abnormality in
human embryos, many groups have developed CCS tech-
nologies capable of identifying smaller deletions and dupli-
cations. This capability is particularly important for patients
carrying a balanced translocation since clinically significant
imbalances of smaller segments of the chromosomes (seg-
mental aneusomy) involved are often produced during mei-
osis. A number of CCS methods have been applied to
evaluating embryos from translocation carrier patients in-
cluding mCGH with a resolution of 10–20 Mb [29] and 25–
100 Mb [30], aCGH with a resolution of 2.8 Mb [31] and
2.5 Mb [32], and SNP arrays with a resolution of 2.4 Mb
[33] and 5 Mb [34]. Despite these reported abilities to detect
small imbalances, the ability to predict de novo deletions
and duplications in embryos from patients without a known
translocation has typically not been claimed. However, a
method combining aCGH and SNP array technologies sug-
gested the ability to detect a 1.7 Mb deletion in single cells
[28] and to predict de novo deletions and amplifications in
human embryos [35]. Estimates of the prevalence of such
imbalances in human embryos by this methodology are high
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382 J Assist Reprod Genet (2012) 29:381–390given their rarity in clinically recognized pregnancies [36,
37]a n dm a yn e e dt ob ec o n f i r m e db ya l t e r n a t i v e
methodologies.
Another key difference between array based platforms is
the way in which copy number is assigned for each chromo-
some. For example, aCGH involves differential labeling and
mixing of biopsy DNAwith control DNA prior to hybridiza-
tion and interpretation of ratios of red and green (two-color)
fluorescence upon completion [38]. In contrast, Affymetrix
SNP arrays involve hybridization of only biopsy DNA (single
color) followed by computational comparison of signal inten-
sities to those obtained on separate control DNA hybridized
arrays (in silico controls) [39]. The SNP single color array
approach has the distinct advantage of evaluating the test
sample against a large number of control samples (not just 1).
This could help avoid inconsistencies from control sample
specific natural variations in the human genome. However,
aCGH platforms are typically designed with probes that avoid
regions of the genome with polymorphic copy number varia-
tions. The aCGH two-color approach has the advantage of
paired comparison to a control sample produced during the
same timeframe and with the same lot of reagents used for the
test sample. This could help control for fluctuations in labora-
tory components used in the process over time.
While CGH methodologies provide an assessment of
chromosomal copy number, SNP arrays and qPCR can also
provide genotypic information which can be used for the
assessment/diagnosis of multiple other clinical factors.
These include single gene disorders, uniparental disomy
(UPD), loss of heterozygosity (LOH), DNA fingerprinting
and determination of the parental and cell division origins of
aneuploidy. Although simultaneous aneuploidy (using
mCGH [24, 40, 41] and SNP arrays [18, 42]) and single
gene (using conventional PCR) analysis has been reported,
SNP array based haplotype methodologies provide the abil-
ity to avoid the time and expense of preparing PCR based
family specific informative markers of the mutation but may
be limited when additional family members are not available
to define haplotype phases. A recent study illustrated the use
of SNP arrays to predict inheritance of monogenic disease
through haplotype based analysis [17] and has applied the
methodology clinically [43]. Another group presented a
similar application of SNP arrays with results confirmed
from antenatal analysis of 3 pregnancies [44].
A number of groups using SNP arrays have used the tech-
nology to predict the parental and cell division origins of
embryonic aneuploidy. One recent publication indicated an
accuracy of 100% for predicting the parental origin of mono-
somy (26/26 male embryo X chromosomes identified as ma-
ternal), and 50% for trisomy [35]. Treff et al. (2008) [45]n o t
only modeled monosomy by evaluating the X chromosome
from male embryos, but also used embryos with trisomies
knowntooriginatefrommaternalmeiosis(asaresultofhaving
evaluated the polar bodies from the same oocyte that the
embryo was derived from) and demonstrated 100% accuracy
for identifying both monosomy and trisomy parental origin of
aneuploidyfromSNParray dataalone[45]. Othergroups have
describedresultsofpredictingtheparentaloriginofaneuploidy
buthaveyettoreportlevelsofaccuracyfromcontrols[16,46].
Furthermore, some methods have been applied to distinguish
meiotic from mitotic aneuploidy by investigating the patterns
of crossover and haplotype inheritance [16, 47]. Validation of
these methods in single cells also remains to be presented but
could represent an important advancement towards improving
ourunderstandingoftheoriginandetiologyofpreimplantation
aneuploidy.Furtherresearchintotheaccuracyofpredictingthe
cell division origins of aneuploidy in human embryos by SNP
array technology are of particular clinical importance since
they have been proposed to serve as a means to justify the
transfer of embryos with aneuploid results [48].
Although uniparental isodisomy may represent an extreme-
ly rare event, the possibility of detection has been validated
using SNP array technology through loss of heterozygosity
(LOH) analysis [49]. LOH analysis can also be useful in con-
firming the presence of a monosomy identified through copy
number based analyses [15]. In contrast, the ability to identify
uniparental heterodisomy has yet to be validated but is theoret-
ically possible given the ability to predict the parental origin of
aneuploidy. Finally, DNA fingerprinting from SNP array data
Fig. 1 A prospectiverandomizedblindedstudydesigned tocompare the
level of reliability and consistency of 2 methods of aneuploidy screening.
Arrested cleavage stage embryos can be dispersed into individual blasto-
meres and then randomly assigned to analysis by either of 2 methods of
analysis (i.e. FISH and SNP microarray). By including more than one
embryo in the randomization, the embryo of origin of each blastomere
can also remain blinded, thereby avoiding the potential bias from know-
ing that 2 blastomeres originated from the same embryo. Results can
demonstrate which method provided the most reliable and consistent
diagnosis. Adapted from Treff et al. [55], and used with permission from
Oxford University Press
J Assist Reprod Genet (2012) 29:381–390 383provides an opportunity to prevent misdiagnosis from contam-
ination and also to identify and track which embryo implanted
after multiple embryo transfer [50]. The later of these finger-
printing applications provides a unique opportunity to perform
very well controlled paired analyses of putative markers of, or
the impact of interventions on the reproductive potential of
sibling embryos [51].
Despite the numerous differences between platforms of
CCS, very little is known about the comparative perfor-
mance of each laboratory specific methodology. Still, com-
parative data may be critical to a better understanding of the
limitations and capabilities of various CCS methodologies
and to providing patients with the best possible care. Some
comparative studies of methodologies within groups have
been performed. For example, mCGH and SNP arrays [52],
and qPCR and SNP arrays [26] have indicated similar levels
of performance. In contrast, a comparative study between
aCGH and SNP arrays indicated aCGH methodology to
have a significant decrease in diagnostic accuracy compared
to SNP arrays [53]. However, a recent study found that
other platforms for aCGH (BlueGnome) and SNP arrays
(Illumina) were highly concordant [54]. Additional com-
parative studies, not just across platforms but also
across laboratories, remain critical to identifying the
most accurate methodologies of CCS.
Comparison of CCS and FISH
With the development of new methods for aneuploidy screen-
ing such as CCS, studies of the putative limitations of FISH
based methods have begun to emerge. One of these studies
involved a novel prospective randomized blinded analysis of
multiple single blastomeres from the same cleavage stage
embryos using either FISH or SNP array based CCS (Fig. 1)
[55]. Randomization of blastomeres from the same embryo to
analysis by either of the two methods provided a unique
opportunity to distinguish between the contribution of mosa-
icism (biological error) or technical error by assessing the rate
of discordance observed by each method. That is, the rate of
discordance within each embryo should be similar for each
method used since mosaicism should be equally distributed
(randomly) to the two methods. However, FISH predicted
100% mosaicism while SNP arrays found only 31% mosai-
cism (Fig. 1) indicating that FISH is an inconsistent technol-
ogy. This is particularly significant since the SNP array data
included more chromosomes per cell, and more cells per
embryo (as a result of significantly higher reliability of diag-
nosis), both of which would increase the chances of finding
mosaicism in the SNP array group.
A second study comparing FISH and CCS analysis of the
same embryos involved careful evaluation of the putative
Fig. 2 A prospective randomized blinded study designed to determine
the accuracy of a single cell CCS methodology. Cell lines with previ-
ously well characterized chromosomal abnormalities can be obtained
from a number of commercial suppliers such as the Corriel Cell
Repository (Camden, NJ). Lines with consistent abnormalities ob-
served in multiple evaluations by the supplier may provide the most
consistent single cells in terms of possessing the expected karyotype.
Single cells can be obtained, placed in PCR tubes, and randomized and
blinded for analysis by CCS. Once CCS predictions are made, the
origin of each cell can be unblinded to evaluate the consistency with
the expected karyotype and the accuracy of the CCS methodology can
be determined
384 J Assist Reprod Genet (2012) 29:381–390mechanisms of “self correction,” [49] which represents the
primary explanation for discordance between cleavage stage
FISH and reanalysis of the resulting blastocysts. For example,
one proposed mechanism of correction is trisomy/monosomy
rescue through extrusion or duplication of a trisomic or mono-
somic chromosome, respectively. This phenomenon can be
expected to lead to uniparental disomy (UPD) in a certain
percentage of blastocysts. Unlike previous studies that have
used FISH to reanalyze blastocysts, originally diagnosed as
abnormal on day 3, SNP array based analysis provides an
opportunity to investigate the possibility of self correction
resulting in UPD. The study by Northrop et al. (2010) [49]
indicated thattrisomy/monosomy rescue is notthe major mech-
anism for “self correction” as 0% of the “corrected” chromo-
somes (n0204) displayed UPD after evaluation with SNP
arrays [49]. Another possible mechanism of correction is pref-
erential segregation of abnormalities to the trophectoderm.
Multiple CCS studies have now demonstrated that preferential
segregation does not occur [49, 56, 57]. However, a potential
limitation of interpretation from blastocyst reanalysis by CCS
methodologies is the inability to detect the presence of mosa-
icism within a multi-cell biopsy. Northrop et al. (2010) [49]
specifically validated the ability to detect a level of mosaicism
of 40% within a 5-cell sample and therefore provided more
weight to evidence for a lack of preferential segregation [49].
While it is still possible that complete extrusion or apoptosis
of aneuploid cells may result in correction of abnormalities in
the embryo upon blastulation, no evidence currently exists to
support such a phenomenon.
One of the major implications of these comparative studies
is that the mitotic origin of embryonic aneuploidy may have
been overestimated. Indeed, studies of products of conception
have found that maternal meiosis is the predominant origin of
aneuploidy [58], and not mitosis as some methods of PGS
have predicted. While traditional cytogenetic analysis (G-
banding) may underestimate the levels of mosaicism in prod-
ucts of conception, recent molecular cytogenetic studies have
shown that “actual” levels of mosaicism may only be higher
by a marginal percentage [36, 37]. In fact, methods which
predict high levels of mosaicism in embryos may need to be
re-evaluated as illustrated in Fig. 1 in order to distinguish
between biological phenomena and technical inconsistency.
This design could also represent an important component to
preclinical validation of embryonic CCS methodologies. Still,
Fig. 3 A prospective blinded non-selection study designed to deter-
mine the negative predictive value of a CCS methodology for the
reproductive potential of the oocyte or embryo. Biopsies of either polar
bodies from the oocyte, a blastomere from the cleavage stage embryo,
or trophectoderm from the blastocyst can be performed. The best
embryos can be selected for transfer based on conventional criteria
and without the use of CCS results. DNA from the conceptus can be
obtained and evaluated against the DNA from the original biopsies in
order to determine which oocytes or embryos produced the newborns.
The percentage of oocytes or embryos predicted to have possessed
aneuploidy by the CCS methodology and that produced euploid
newborns can be calculated. This value subtracted from 100% gives
the negative predictive value and whether the CCS methodology can
be used to safely discard an embryo
J Assist Reprod Genet (2012) 29:381–390 385the phenomenon of mosaicism cannot be completely disre-
garded given observations from other studies involving CCS
analysis of multiple cells from the same embryo [11, 59].
Evidence for CCS
Given the inconsistency and poor negative predictive value
of cleavage stage FISH, new technologies such as CCS
should be more carefully evaluated. Moreover, FISH based
re-analysis of CCS evaluated embryos may not represent a
good approach to validate new CCS methods since FISH has
been shown to be an inconsistent methodology itself. Alter-
natively, randomized blinded analysis of single cells from cell
lines with known abnormalities could be performed and used
to evaluate the accuracy of aneuploidy predictions (Fig. 2).
Another interesting study design for evaluating the accuracy
of a CCS methodology was recently performed by the Euro-
pean Society of Human Reproduction and Embryology
(ESHRE) Task Force on PGS [60]. In this blinded pilot study,
polar body CCS results were obtained using aCGH and com-
pared to the results of the corresponding oocytes for consis-
tency, which was found to be 94% (130/138).
As previously alluded to, accumulating evidence indicates
that FISH based aneuploidy screening at the cleavage stage of
embryogenesis is not only inconsistent but also poorly pre-
dictive of aneuploidy in the blastocyst. Reanalysis of blasto-
cysts indicate that nearly 60% of embryos discarded due to an
abnormal cleavage stage FISH diagnosis were in fact euploid
for all 24 chromosomes in all 4 evaluated sections [49]. A
similar observation was recently made from reanalysis of
blastocysts originally given a parental support based CCS
abnormal cleavage stage diagnosis [61]. Parental support
based CCS reanalysis results indicated that 43% of the blas-
tocysts (26/61) wereeuploid despite ananeuploid diagnosis at
the cleavage stage. It is unclear whether these discrepancies
were due to biological variation or technical issues with pa-
rental support. These observations highlight the critical need
for a second preclinical validation study; to determine the
negative predictive value of CCS for embryonic reproductive
potential [62]. Such a study could indicate whether the CCS
methodiscapable ofaccuratelydetermining the chromosomal
status of embryos so that there is high confidence that embry-
os being discarded are truly abnormal (Fig. 3). Oocytes or
embryos would be biopsied and selected for transfer using
conventional morphological and developmental criteria with-
out information from CCS. The CCS results of each biopsy
wouldbeproducedonlyafterembryotransferhadtakenplace.
Specific outcomesofeachindividualoocyteorembryowould
be confirmed by DNA fingerprinting [50]a n dt h ei m p l a n t a -
tion and delivery from oocytes or embryos that would have
been diagnosed as aneuploid by CCS could be determined.
However, since some CCS methods don’t provide
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386 J Assist Reprod Genet (2012) 29:381–390polymorphism information (i.e. mCGH and aCGH), addition-
al molecular tests would be required in order to track embryo
specific outcomes. This approach should be possible even for
those groups using CGH methodologies given previous
reports of double factor PGD [40, 41]. In the situation where
polar body biopsy is performed, an alternative method of
embryo tracking from polar body polymorphisms could be
employed [63]. While a randomized controlled trial is neces-
sary to evaluate the efficacy of a particular CCS method it
would fail to determine the negative predictive value of the
method since samples predicted to possess aneuploidy
would not be transferred. This is particularly trouble-
some for patients when all their embryos or oocytes are
predicted to be aneuploid. Without the knowledge that
the negative predictive value of a method is meaningful,
one will never know if implementation of the method pre-
vented such a patient from missing out on the opportunity of
having a healthy child. A prospective blinded non-selection
clinical trial is therefore a critical consideration when estab-
lishing the safety of CCS methodologies.
Although a randomized controlled trial represents what
most consider the pinnacle of clinical validation of efficacy,
case–control studies currently represent the primary source
of evidence of clinical validity for most CCS methodologies
[12, 64–68]. While it is certainly encouraging to see
improvements from such analyses, it should be noted that
many cleavage stage FISH case–control studies illustrated
significant clinical improvements [69–73] but ultimately
failed in all randomized controlled trials performed to date
[4]. As a result of the higher standard of evidence that
randomization provides, many CCS methodologies have
now initiated the process of conducting randomized con-
trolled trials (Table 2). The results presented for one these
CCS methods has indicated a significant increase in clinical
pregnancy and embryo implantation rates [26].
Future of CCS
While numerous considerations for the efficacy of using a
specific stage of biopsy for PGS exist, one of the most impor-
tant may be the impact that the procedure has on the repro-
ductive potential of the embryo. Although some studies have
focused on comparing outcomes in patients who had all of
their oocytes/embryos biopsied to outcomes in patients who
had none of their oocytes/embryos biopsied, this may not
represent the best controlled study design. This is particularly
true since the patients having embryos or oocytes biopsied
were typically subject to PGS while the other patients were
not. Instead, randomization of the 2 best oocytes/embryos so
that one is biopsied (case) and the other is not (control) and
subsequent paired analysis of outcomes within each 2 embryo
transfer (using DNA fingerprinting) could represent a better
controlled study of the impact of biopsy. Interestingly, prelim-
inary results using this paired study design indicate that em-
bryo biopsy at the cleavage stage, but not the blastocyst stage,
significantly reduces the implantation potential of the embryo
[74]. Similar studies of the impact of polar body biopsy have
yet tobeconducted but should be helpful incharacterizing the
safety and optimum stage of biopsy for CCS.
While validated methods of CCS may improve clinical out-
comes for patients with infertility, they may also represent an
exciting tool to help identify additional markers, beyond aneu-
ploidy screening, that provide predictive information about the
long term viability of embryos and oocytes. Indeed, this objec-
tive represents one of the most important challenges in repro-
ductive medicine [75]. Since it is clear that not all embryos,
identified as euploid by CCS, ultimately result in the delivery of
a newborn, there are likely additional markers of reproductive
potential that may enhance the precision of embryo selection.
Once validated methods of CCS have been established, re-
search efforts can be directed at characterizing molecular and
biochemical signatures of embryos that are morphologically
and chromosomally normal. One of the first studies to employ
this design involved determining cumulus cells gene expression
signatures predictive of which morphologically and chromo-
somally normal embryos possess reproductive potential [51].
This is different from simply evaluating whether cumulus cells
c a nb eu s e da sa na l t e r n a t i v et od i r e c to o c y t eo re m b r y oC C S
aneuploidy screening[76]orwhethercumuluscellscanbeused
to select competent oocytes or embryos without simultaneous
aneuploidy screening [77]. The unique aneuploidy controlled
study design could apply to evaluating additional types of
molecular signatures including, for example, the embryonic
metabolome [78]o rp r o t e o m e[ 79, 80].
Despite the failure of cleavage stage FISH based aneuploi-
dy screening, the introduction ofnew CCS technologiesholds
great promise for achieving the expected improvements in
clinical outcomes for patients suffering from infertility. A
critical mass of class I evidence still needs to be generated
for each CCS methodology before scientists and clinicians
adopt it for routine clinical testing. Randomized controlled
trials of efficacy as well as non-selection studies of the nega-
tive predictive value of embryonic reproductive potential
should provide the data needed to accept or reject the validity
of a given CCS methodology. While recent success of blasto-
cysttrophectodermCCSwithqPCRandfreshembryotransfer
is encouraging, results from additional ongoing randomized
trialsofCCSareeagerlyanticipatedandshouldhelpshapethe
future of chromosome screening in the IVF setting.
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